Skip to main content
64°
Mostly Cloudy
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Xenon Pharmaceuticals Inc.
Xenon Expands Leadership Team with Matthew D. Ronsheim, Ph.D. as Chief Operating Officer
August 12, 2024
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Tickers
XENE
Xenon Reports Q2 2024 Financial Results and Business Update
August 08, 2024
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Tickers
XENE
Xenon to Report Q2 2024 Financial Results on August 8, 2024
August 01, 2024
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Tickers
XENE
Xenon Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
June 05, 2024
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Tickers
XENE
Xenon Pharmaceuticals Presents Data from Phase 2 X-NOVA Clinical Trial of Azetukalner in Major Depressive Disorder at the American Society of Clinical Psychopharmacology 2024 Annual Meeting
May 28, 2024
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Tickers
XENE
Xenon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 09, 2024
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Tickers
XENE
Xenon Pharmaceuticals to Present at the BofA Securities Health Care Conference 2024
May 08, 2024
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Tickers
XENE
Xenon Pharmaceuticals to Present at the 2024 RBC Capital Markets Global Healthcare Conference
May 07, 2024
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Tickers
XENE
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Corporate Update
May 02, 2024
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Tickers
XENE
Xenon Pharmaceuticals Showcases XEN1101 at the American Academy of Neurology 2024 Annual Meeting
April 16, 2024
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Tickers
XENE
Xenon Pharmaceuticals to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
April 10, 2024
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Tickers
XENE
Xenon Pharmaceuticals to Present at the 23rd Annual Needham Virtual Healthcare Conference
April 04, 2024
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Tickers
XENE
Xenon Pharmaceuticals to Present at Stifel 2024 Virtual CNS Days
March 12, 2024
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Tickers
XENE
Xenon Pharmaceuticals to Present at Leerink Partners Global Biopharma Conference 2024
March 05, 2024
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Tickers
XENE
Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
February 29, 2024
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Tickers
XENE
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update
February 22, 2024
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Tickers
XENE
Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2024
January 08, 2024
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Tickers
XENE
Xenon Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Tickers
XENE
Xenon Pharmaceuticals Announces Closing of $345.0 Million Upsized Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
December 04, 2023
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Tickers
XENE
Xenon Pharmaceuticals Provides Updates on Neurology Pipeline Programs at the Annual Meeting of the American Epilepsy Society (AES 2023)
December 02, 2023
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Tickers
XENE
Xenon Pharmaceuticals Announces Pricing of Upsized $300.0 Million Public Offering
November 29, 2023
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Tickers
XENE
Xenon Pharmaceuticals Announces Proposed Public Offering
November 29, 2023
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Tickers
XENE
Xenon Pharmaceuticals Announces Topline Results from Phase 2 Proof-of-Concept X-NOVA Clinical Trial of XEN1101 in Major Depressive Disorder (MDD)
November 27, 2023
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Tickers
XENE
Xenon Pharmaceuticals Provides Update on Partnered Program with Neurocrine Biosciences
November 09, 2023
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Tickers
XENE
Xenon Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 08, 2023
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Tickers
XENE
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Third Quarter 2023 Financial Results and Provide Corporate Update
November 01, 2023
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Tickers
XENE
Xenon Pharmaceuticals Announces Publication of Results from XEN1101 Phase 2b “X-TOLE” Clinical Trial in Peer-Reviewed Journal Article in JAMA Neurology
October 09, 2023
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Tickers
XENE
Xenon Pharmaceuticals to Present at Jefferies Inaugural Biotech CNS/Neuro Summit
October 06, 2023
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Tickers
XENE
Xenon Pharmaceuticals to Present at TD Cowen’s 3rd Annual Novel Mechanisms in Neuropsychiatry Summit
September 14, 2023
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Tickers
XENE
Xenon Pharmaceuticals Announces Upcoming Investor Webinar with Leading Key Opinion Leaders to Discuss XEN1101 and Major Depressive Disorder
September 12, 2023
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Tickers
XENE
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.